Ajanta Pharma Ltd
AJANTPHARMBSE 532331PharmaceuticalsMkt cap ₹44,763 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹1,626 Cr
YoY +24.8%QoQ +14.4%
Net profit · Q1 FY27
₹334 Cr
YoY +30.9%QoQ +25.3%
Net margin · Q1 FY27
20.6%
+1.0 pts vs Q1 FY26
Net profit · FY26
₹1,056 Cr
YoY +14.7%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 1,626 | 1,422 | 1,375 | 1,354 | 1,303 | +24.8% |
| Other income | 70.90 | 61.43 | 24.97 | 59.34 | 26.33 | +169.3% |
| Total income | 1,697 | 1,483 | 1,400 | 1,413 | 1,329 | +27.7% |
| Profit before tax | 447 | 347 | 359 | 341 | 331 | +34.9% |
| Tax | 113 | 80.41 | 84.83 | 80.62 | 75.79 | +48.5% |
| Net profit | 334 | 267 | 274 | 260 | 255 | +30.9% |
| Net margin | 20.6% | 18.8% | 19.9% | 19.2% | 19.6% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 5,453 | 4,648 | 4,209 | 3,743 | 3,341 | +17.3% |
| Other income | 172 | 94.50 | 84.60 | 98.64 | 116 | +82.1% |
| Total income | 5,625 | 4,743 | 4,293 | 3,841 | 3,457 | +18.6% |
| Profit before tax | 1,378 | 1,189 | 1,114 | 745 | 909 | +15.9% |
| Tax | 322 | 269 | 298 | 157 | 197 | +19.7% |
| Net profit | 1,056 | 920 | 816 | 588 | 713 | +14.7% |
| Net margin | 19.4% | 19.8% | 19.4% | 15.7% | 21.3% |
BIC's take
We haven't covered Ajanta Pharma Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:40 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.